Logo

TLX

Telix Pharmaceuticals Limited

TLX

Telix Pharmaceuticals Limited • NASDAQ
$9.95 ▲ 2.05% (+0.20)
Market Cap $3.37 B
52w High $30.36
52w Low $8.76
Dividend Yield 0%
P/E 497.5
Volume 23.04K
Outstanding Shares 338.49M

Income Statement

Period Revenue Operating Expense Net Income Net Profit Margin Earnings Per Share EBITDA
Q2-2025 $593.111M ▼ $272.556M ▼ $-3.482M ▼ -0.587% ▼ $-0.01 ▼ $8.905M ▼
Q4-2024 $594.244M ▲ $317.419M ▲ $38.239M ▲ 6.435% ▲ $0.12 ▲ $76.8M ▲
Q2-2024 $188.963M ▼ $110.129M ▼ $11.68M ▼ 6.181% ▼ $0.035 ▼ $40.291M ▲
Q4-2023 $281.713M ▲ $203.9M ▲ $19.531M ▲ 6.933% ▲ $0.06 ▲ $22.994M ▲
Q2-2023 $220.834M $59.373M $-14.32M -6.485% $-0.045 $-8.573M

Balance Statement

Period Cash & Short-term Total Assets Total Liabilities Total Equity
Q2-2025 $207.156M ▼ $1.19B ▼ $768.011M ▼ $421.941M ▼
Q4-2024 $710.346M ▲ $1.516B ▲ $948.218M ▲ $568.213M ▲
Q2-2024 $118.837M ▼ $745.958M ▲ $341.984M ▲ $403.974M ▲
Q4-2023 $123.237M ▼ $398.302M ▲ $249.391M ▲ $148.911M ▲
Q2-2023 $131.729M $310.336M $231.836M $76.057M

Cash Flow Statement

Period Net Income Cash From Operations Cash From Investing Cash From Financing Net Change Free Cash Flow
Q2-2025 $-3.482M ▲ $26.968M ▲ $-393.303M ▼ $-4.441M ▼ $314.753M ▼ $16.836M ▲
Q4-2024 $-11.68M ▼ $3.948M ▼ $-89.332M ▼ $635.305M ▲ $591.509M ▲ $-10.916M ▼
Q2-2024 $11.68M ▼ $34.979M ▲ $-45.622M ▼ $3.618M ▼ $-3.871M ▲ $19.913M ▲
Q4-2023 $19.531M ▲ $10.625M ▼ $-22.603M ▼ $5.485M ▲ $-8.492M ▼ $2.84M ▼
Q2-2023 $-14.32M $13.259M $-2.886M $4.701M $15.4M $10.25M

Revenue by Products

Product Q1-2013Q3-2013Q2-2016Q2-2019
Digital Product Lease And Maintenance
Digital Product Lease And Maintenance
 $0 ▲$0 ▲$0 ▲$0 ▲
Digital Product Sales
Digital Product Sales
 $0 ▲$0 ▲$0 ▲$10.00M ▲
Digital Display
Digital Display
 $0 ▲$0 ▲$0 ▲$0 ▲
Digital Display Lease And Maintenance
Digital Display Lease And Maintenance
 $0 ▲$0 ▲$0 ▲$0 ▲

Five-Year Company Overview

Income Statement

Income Statement Telix has moved from being a pure research company with minimal sales to a commercial-stage business with fast-growing revenue. Over just a few years, sales have climbed sharply, and the company has shifted from meaningful losses to posting profits at the operating and net income level. Margins have improved as Illuccix sales have scaled, showing that the core product can support a profitable model. However, the business is still relatively young, with profits emerging only recently and still highly dependent on a limited number of products, so earnings could be volatile as the pipeline advances and as competition and pricing pressures evolve.

Balance Sheet

Balance Sheet The balance sheet has expanded significantly as Telix has grown, with total assets and cash balances both rising strongly. The company now holds a solid cash cushion relative to its past, which helps support its large research and clinical programs. At the same time, debt has increased from almost nothing to a meaningful level, introducing leverage that was not present before. Equity has grown alongside this, reflecting accumulated profits and capital raised, but the business now needs to manage its higher debt load carefully while continuing to invest heavily in growth and regulatory approvals.

Cash Flow

Cash Flow Telix has transitioned from consistently burning cash to beginning to generate cash from its operations, which is a key milestone for any biotech moving into commercialization. Free cash flow has also turned slightly positive, helped by only modest spending on equipment and facilities so far. This means the company is increasingly funding its activities from its own sales rather than relying entirely on external capital. That said, cash generation is still relatively thin compared with the scale of its R&D ambitions and clinical pipeline, so cash flows could swing back and forth depending on trial costs, regulatory requirements, and any manufacturing investments needed.

Competitive Edge

Competitive Edge Telix occupies a strong niche in radiopharmaceuticals, built around its theranostic model of using the same targeting approach for both imaging and treatment. Illuccix has given the company a foothold in prostate cancer imaging and brand recognition with oncologists and imaging centers. Telix has tried to deepen its moat through control of the supply chain, manufacturing assets, and regulatory know-how, which are all meaningful barriers to entry in this space. The pipeline covers several major cancers, which reduces reliance on a single indication over the long term. However, Telix competes against larger pharma and imaging companies, operates in a highly regulated area with complex manufacturing, and now faces added uncertainty from legal actions and regulatory scrutiny, all of which can weigh on its competitive standing and reputation.

Innovation and R&D

Innovation and R&D Innovation is the core of Telix’s strategy. The company is pushing a broad platform in targeted radiation, combining diagnostics and therapy for prostate, kidney, and brain cancers, and increasingly exploring newer areas like alpha therapies, AI in imaging, and radio-guided surgery tools. Multiple late-stage and mid-stage trials, especially in prostate and kidney cancer, could materially reshape the company’s profile if successful. Acquisitions have expanded its technology base into new biologic targets and early-stage assets, aiming to create a long-lived product pipeline rather than a single-product story. Still, the usual biotech risks apply: clinical failures, delays, manufacturing issues, or additional regulatory feedback could disrupt timelines and increase costs, and the recent regulatory setback for a kidney cancer imaging product highlights how execution risk remains significant.

Summary

Overall, Telix is evolving from a research-heavy biotech into a commercial radiopharmaceutical company with real revenue, improving profitability, and early positive cash generation. Financially, it now has more resources and a larger balance sheet, but it also carries more debt and ongoing heavy investment needs. Strategically, its theranostic focus, supply-chain control, and growing portfolio of cancer programs provide a differentiated position in a high-potential niche. At the same time, the business is still relatively early in its commercial life, heavily dependent on a few key products, and exposed to clinical, regulatory, manufacturing, and legal risks that could create bumps in both operational and financial performance. For observers, Telix represents a classic high-innovation, higher-uncertainty biotech story: compelling scientific and commercial momentum, balanced by the need for careful attention to execution, regulation, and risk management over the coming years.

NEWS

November 29, 2025 · 5:31 PM UTC

ROSEN, RECOGNIZED INVESTOR COUNSEL, Encourages Telix Pharmaceuticals Ltd. Investors to Secure Counsel Before Important Deadline in Securities Class Action First Filed by the Firm - TLX

Read more

November 29, 2025 · 8:45 AM UTC

SHAREHOLDER ALERT: Faruqi & Faruqi, LLP Investigates Claims on Behalf of Investors of Telix Pharmaceuticals

Read more

November 28, 2025 · 5:26 PM UTC

ROSEN, A LEADING INVESTOR RIGHTS LAW FIRM, Encourages Telix Pharmaceuticals Ltd. Investors to Secure Counsel Before Important Deadline in Securities Class Action First Filed by the Firm - TLX

Read more

November 28, 2025 · 5:25 PM UTC

Telix Pharmaceuticals (TLX) Sued After Alleged Misstatements on Prostate Cancer Drug Progress and Supply Chain Reliability-- Hagens Berman

Read more

November 28, 2025 · 11:44 AM UTC

Bragar Eagel & Squire, P.C. Reminds Investors of Telix Pharmaceuticals and Firefly Aerospace to Contact the Firm About their Rights Before Lead Plaintiff Deadlines

Read more